El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
Español (Latinoamérica)
Artivion Inc
Abierto
SectorSalud
36.7 -2.03
Resumen
Variación precio
24h
Mínimo
36.47
Máximo
37.58
Ingresos | -4.1M 2.4M |
|---|---|
Ventas | 2.6M 116M |
P/B Media del Sector | 171.857 61.417 |
Margen de beneficio | 2.092 |
Empleados | 1,800 |
EBITDA | -6M 13M |
Recomendaciones | Compra Fuerte |
|---|---|
Estimación a 12 meses | +36.82% upside |
Próximas Ganancias | 4 may 2026 |
|---|
Capitalización de Mercado | -148M 1.7B |
|---|---|
Apertura anterior | 38.73 |
Cierre anterior | 36.7 |
Noticias sobre sentimiento de mercado
By Acuity
50%
50%
156 / 351 Clasificación en Healthcare
Artivion Inc Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Artivion Inc Esperado
Precio Objetivo
By TipRanks
36.82% repunte
Estimación a 12 meses
Media 51.17 USD 36.82%
Máximo 58 USD
Mínimo 41 USD
De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Artivion Inc Dist en los últimos 3 meses.
Sentimiento
By Acuity
156 / 351 Clasificación en Salud
Noticias sobre sentimiento de mercado
Neutral
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por debajo de la media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Artivion Inc
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
Live chat